4-propoxy-1-indanone | 820238-22-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 4-propoxy-1-indanone
• 英文别名: 4-Propoxy-2,3-dihydro-1H-inden-1-one；4-propoxy-2,3-dihydroinden-1-one
• CAS: 820238-22-0
• 化学式: C₁₂H₁₄O₂
• 分子量: 190.242
• InChiKey: KPTQUFFGBQHGDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-propoxy-1-indanone 、 3-甲氧基-4-[(四氢-2H-吡喃-2-基)氧基]苯甲醛 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成
  参考文献：
  名称：

  2-亚苄基-1-茚满酮衍生物的设计、合成和构效关系作为治疗急性肺损伤的抗炎剂

  摘要：

  Purpose: The purpose of this study was to design and synthesize novel 2-benzylidene-1-indanone derivatives for treatment of acute lung injury.Methods: A series of 39 novel 2-benzylidene-indanone structural derivatives were synthesized and evaluated for anti-inflammatory activity in lipopolysaccharide (LPS)-stimulated murine primary macrophages.Results: Most of the obtained compounds effectively inhibited the LPS-induced expression of IL-6 and TNF-alpha. The most active compound, 8f, was found to significantly reduce LPS-induced pulmonary inflammation, as reflected by reductions in the concentration of total protein, inflammatory cell count, as well as the lung wet/dry ratio in bronchoalveolar lavage (BAL) fluid. Furthermore, 8f effectively inhibited mRNA expression of several inflammatory cytokines after LPS challenge in vitro and in vivo. Administration of 8f also blocked LPS-induced activation of the proinflammatory NF-kappa B/MAPK signaling pathway.Conclusion: The simple synthetic preparation and biological properties of these derivatives make these 2-benzylidene-indanone scaffolds promising new entities for the development of anti-inflammatory therapeutics for the treatment of acute lung injury.

  DOI：

  10.2147/dddt.s160314
• 作为产物：
  描述：

  4-羟基-1-茚酮 、 1-碘代丙烷 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 7.0h， 生成 4-propoxy-1-indanone
  参考文献：
  名称：

  [EN] TRICYCLIC PYRAZOLE KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASES A BASE DE TYRAZOLES TRICYCLIQUES

  摘要：

  本发明的化合物对抑制蛋白酪氨酸激酶具有用处。还公开了制备这些化合物的方法、含有这些化合物的组合物以及使用这些化合物进行治疗的方法。

  公开号：

  WO2005095387A1

文献信息

• Tricyclic pyrazole kinase inhibitors
  申请人：Arnold D. Lee

  公开号：US20060014816A1

  公开（公告）日：2006-01-19

  Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  本发明的化合物可用于抑制蛋白酪氨酸激酶。还公开了制备该化合物的方法，含有该化合物的组合物，以及使用该化合物的治疗方法。
• Pyrazolidinedione derivatives
  申请人：Fretz Heinz

  公开号：US20070037846A1

  公开（公告）日：2007-02-15

  The present invention relates to compounds of alkylidene pyrazolidinedione derivatives, which are effective platelet ADP receptor antagonists that prevent platelet aggregation and thrombosis. Thus, the present invention also relates to pharmaceutical compositions that contain the compounds as well as methods of preventing or treating peripheral, visceral, hepatic, renal, cardio- and cerebro-vascular diseases and conditions that are associated with platelet aggregation, including thrombosis, in humans and other mammals. The present invention further provides a process for manufacturing the alkylidene pyrazolidinedione derivatives.

  本发明涉及烷基亚胺吡唑啉二酮衍生物化合物，其为有效的血小板ADP受体拮抗剂，可预防血小板聚集和血栓形成。因此，本发明还涉及包含该化合物的制药组合物，以及用于预防或治疗与血小板聚集有关的外周、内脏、肝、肾、心血管和脑血管疾病和病状的方法，包括血栓形成，在人类和其他哺乳动物中。本发明还提供一种制造烷基亚胺吡唑啉二酮衍生物的方法。
• PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP1638540A2

  公开（公告）日：2006-03-29
• TRICYCLIC PYRAZOLE KINASE INHIBITORS
  申请人：ABBOTT LABORATORIES

  公开号：EP1740579A1

  公开（公告）日：2007-01-10
• US7468371B2
  申请人：——

  公开号：US7468371B2

  公开（公告）日：2008-12-23